Introduction {#sec1}
============

The implantable cardioverter defibrillator (ICD) is widely accepted for primary and secondary prevention of severe life-threatening ventricular tachyarrhythmia. The Heart Rhythm Society updated appropriate use criteria for ICD therapy [@bib1], however the incidence, risk factors, and management of safety margin testen \<10 J (SMT) during implantable cardioverter defibrillator (ICD) testing are not well known.

The first small study in 1995 [@bib2] and more previous studies [@bib3], [@bib4] have demonstrated that additional insertion of a subcutaneous array (SQA) reduces mean defibrillation thresholds (DFT) of 20%--60%, depending on the electrode model used.

The purpose of this study was to assess the efficacy/safety of routinely adding a subcutaneous array (Medtronic 6996SQ) for patients with SMT \<10 J during implantable cardioverter defibrillator (ICD) testing.

Methods {#sec2}
=======

All consecutive patients undergoing initial ICD placement or generator replacement from January 2007 to December 2009 were analyzed in this retrospective, single-centre analysis.

Postimplantation ICD test protocol {#sec2.1}
----------------------------------

Devices of all 4 important international companies (Biotronic, Medtronic, St. Jude Medical, Boston) were implanted. They were implanted in the catheter laboratory by 5 experienced invasive cardiologists. In all patients adequate ventricular sensing (≥9 mV) and pacing threshold (≤1 V) was confirmed. In the absence of absolute contraindications (eg thrombus formation in the left atrial appendage (LAA) or the left ventricle (LV)), an intra-operative ICD testing was routinely performed to prove a correct sensing, processing, shock delivery and termination of an induced VF. Our protocol for intra-operative ICD testing required at least one induction of VF with successful first shock terminating VF at a safety margin of at least 10 Joule (J) below the maximum output of the implanted device. If the first shock was not successful, a second shock at the maximum output of the device was delivered. In case this shock was still not successful an external defibrillation with 360 J biphasic shock was added. Patients with the need of a second shock at the maximum output or an external defibrillation to terminate induced VF were considered as ineffective SMT and were included in our study. Further management of these patients included intra-operative right ventricular lead reposition or an ICD-system modification such as addition or subtraction of the superior vena cava (SVC) shock coil and polarity reversal, respectively. In case the SMT was still ineffective, the implantation of a subcutaneous electrode array, considered to be the most effective method for reducing defibrillation threshold, was planned.

Subcutaneous electrode array Medtronic 6996SQ {#sec2.2}
---------------------------------------------

The subcutaneous array electrode Medtronic 6996SQ consists of a single defibrillating coil of 25 cm length and has a diameter of 7.5 F, and an electrical cord ending with a 3.2 mm connector type DF-1. Total length of the electrode is 41 cm or 58 cm. That system is connected to the SVC socket of the implanted ICD. If a dual-coil intravascular lead is used, the subcutaneous electrode may be connected through the Y-connector to the SVC socket together with the proximal coil of the intravascular lead.

Implantation procedure of the 6996SQ electrode {#sec2.3}
----------------------------------------------

The patient was lying flat, with the left upper limb abducted and an additional support under the left scapula. Local anesthesia was applied in the ICD pocket and along the designed course of the subcutaneous electrode. An incision was made in 10 cm distance of the ICD pocket. A stainless steel tunneling tool (6996ST provided by the manufacturer together with the electrode) with a dedicated sheath on was shaped appropriately and introduced via the small incision and further into the subcutaneous tissue along the chest wall, and towards the region below the inferior angle of the left scapula. Then the tunneling tool was removed and the electrode with an introducer inside was inserted into the sheath. Following that, the sheath was removed with a dedicated slittering tool, and the electrode itself was sutured in the pocket in a manner typical for intravascular leads. The electrode was tunneled from the incision into the ICD pocket and connected to the SVC socket of the ICD. Ideally the electrode along its course remained in the projection of the chest, and its end is located as close to the vertebral column as possible. In case of right sided ICD implantation the procedure itself does not differ from left sided implantations; however, the final tunneling to the ICD pocket has to be performed across the thorax and the end of the SQ array is located much more lateral because of the limited length of the array ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Chest x-ray image (posterior-anterior and lateral projection) of an ICD device plus subcutaneous array electrode (Panel A and B: left sided ICD implantation; Panel C and D: right sided ICD implantation).

Statistical analysis {#sec2.4}
--------------------

The study group consisted of all patients with SMT \<10 J, whereas the control group included all patients who did not develop this problem. Continuous variables were reported as mean value ± standard deviation or median and interquartile ranges (25th--75th percentiles) where appropriate. Categorical variables were presented as absolute (n) and relative (%) frequencies. Normal distribution of variables was assessed using the D\'Agostino-Pearson omnibus normality test. Comparisons of continuous variables were made with the appropriate two-sample test; Student-t-test in cases where the variable was normally distributed. Otherwise, the Kruskal--Wallis test was used to identify risk factors for ILM. A probability value of p ≤ 0.05 was considered statistically significant. Statistical analysis was performed using the GraphPad Prism version 6.02 for windows (GraphPad Software, La Jolla, California, USA).

Results {#sec3}
=======

A total of 1221 patients underwent heart rhythm device implantation during the study period. Out of 632 analyzed ICD-recipients, 16 (2.5%) had no intra-operative defibrillation testing \[9 patients (1.4%) due to left atrial- or left ventricular thrombus and 7 (1.1%) due to decision of the operator (mainly atrial fibrillation with ineffective oral anticoagulation)\]. Included in this retrospective analysis were 616 consecutive patients who received SMT following transvenous ICD implantation or ICD replacement. The population is described in [Table 1](#tbl1){ref-type="table"}; the device flow chart is shown in [Fig. 2](#fig2){ref-type="fig"}.Fig. 2Device flow chart (CCM: cardiac contractility modulation; HRD: heart rhythm devices; ICD: implantable cardioverter defibrillator; ILR: implantable loop recorder; SMT: safety margin testing; SQ: subcutaneous).Table 1Baseline characteristics.AllEffective SMT (≥10 J)Ineffective SMT (\<10 J)p-valueNumber, n (%)616600 (97.4)16 (2.6)SexMale, n (%)469456 (76)13 (81.3)0.77Female, n (%)147144 (24)3 (18.7)Age (years)Mean (±SD)66.4 (±11)66.7 (±10.6)54.6 (±16.5)**0.0003**Median (IQR)69 (60--74)69 (62--74)54 (41--69)LVEF (%)Mean (±SD)31 (±12.4)31 (±12.5)26.9 (±9.0)0.86Median (IQR)30 (22--35)30 (23--35)30 (20--35)LVEF ≤30%, n (%)370 (59.9)359 (59.8)11 (68.8)0.61 (\>30% vs ≤30%)LVEF ≤20%, n (%)284 (46)279 (46.5)5 (31.2)0.31 (\>20% vs ≤20%)BMI (kg/m2)Mean (±SD)28.4 (±4.7)28 (±4.7)29 (±4.0)0.68Median (IQR)28 (17--28)28 (25--31)29 (25.5--33)IndicationPrimary prevention n (%)466 (75.7)453 (75.5)13 (81.3)0.77Secondary prevention n (%)150 (24.3)147 (24.5)3 (18.7)Type of arrhythmia for secondary prevention n (%)sustained VT108 (72)107 (72.8)1 (33.3)p = 0.19 (VT vs VF)VF42 (28)40 (27.2)2 (66.7)SMT-energy (J)Mean (±SD)21 (±2.3)20.8 (±2.3)30.9 (±2.0)**0.0001**Median (IQR)20 (20--22)20 (20--20)30 (30--30)**Diagnosis**Non CAD, n (%)270 (43.5)259 (43.2)11 (68.8)DCM (myocarditis), n (%)232 (37.7)222 (37)10 (62.5)0.06 (myocarditis vs nonmyocarditis)Other CM (non myocarditis), n (%)38 (6.2)27 (6.2)1 (6.3)CAD, n (%)346 (56.2)341 (56.8)5 (31.3)**0.05** (nonCAD vs CAD)Complete revascularized, n (%)196 (56.3)192 (56.3)4 (80)Not complete revascularized, n (%)150 (43.7)149 (43.7)1 (20)0.18 (complete vs in- complete revascularized)MedicationAmiodarone medication, n (%)123 (20)118 (19.7)5 (31.3)0.34No amiodarone, n (%)493 (80)482 (80.3)11 (68.7)[^1]

Effective defibrillation SMT was performed with a mean energy of 20.8 ± 2.3 J. In 16 patients (2.6%) induced VF could only be terminated with the maximum energy of the implanted device or with an external defibrillation ([Table 1](#tbl1){ref-type="table"}). There occurred no severe complications (death, major or minor strokes or cardiogenic shock) in any of the 616 SMT performed. The patients with ineffective SMT were younger (66.7 ± 10.6 years versus 54.6 ± 16.5 years; p = 0.003) and in univariate analysis they were less likely to have CAD as underlying diagnosis (31.3% versus 56.8%; p = 0.05). There was a trend for higher incidence of ineffective SMT in patients with myocarditis/inflammatory dilated cardiomyopathy compared to other form of non-ischemic cardiomyopathy (62.5% versus 37%), however this was not statistically significant (p = 0.06). Variables without impact on the efficiency of SMT included whether or not patients had a LVEF ≥20%, had a secondary preventive indication for ICD, were incomplete revascularized, had more than one main vessel significantly diseased and were taking a medication with amiodarone, respectively ([Table 1](#tbl1){ref-type="table"}).

In all 16 cases, other methods to improve SMT prior to SQ array insertion were attempted but failed for all patients: reversing shock polarity \[n = 15 (93.8%)\], removing the superior vena cava coil \[n = 14 (87.5%)\], reprogramming shock waveform \[n = 9 (56.3%)\], and repositioning right ventricular lead \[n = 9 (56.3%)\]. Addition of the SQ array successfully increased SMT to within safety margin for all patients (30.9 ± 2 J without versus 21 ± 3 J with SQ array; p \< 0.001). No complications related to subcutaneous array implantation occurred in our series.

Arrhythmic events during follow-up {#sec3.1}
----------------------------------

The mean follow up was 48.1 ± 21 months and no death or resuscitation occurred during the follow up period. There were no problems (e.g. lead fracture, infection) noticed related to the subcutaneous array. Antiarrhythmic medication was equally balanced between both groups ([Table 2](#tbl2){ref-type="table"}). In general, there were more events in patients with effective SMT (23.2% versus 12.5%; p = 0.55). There were significantly more adequate therapies in patients with effective SMT (21.4% versus 0%; p = 0.05), whereas inadequate therapies were more frequently encountered in patients with initial ineffective SMT (12.5% versus 0.8%; p = 0.01).Table 2Follow up data.AllEffective SMT (≥10 J)Ineffective SMT (\<10 J)p-valueFollow up, n (%)550 (89.3)534 (89)16 (100)0.40FU duration (months)Mean (±SD)48.1 (±21)52.5 (±21)43.8 (±21)0.56Antiarrhythmic drugs, n (%)Amiodarone128 (23.3)122 (22.9)6 (37.5)0.23Sotalex2 (0.4)2 (0.4)0 (0)1.00β-Blocker500 (90.9)485 (90.8)15 (93.8)1.00Events during FU, n (%)126 (22.9)124 (23.2)2 (12.5)0.55Inadequate therapy6 (1.1)4 (0.8)2 (12.5)**0.01**Adequate therapy114 (20.7)114 (21.4)0 (0)**0.05**ATP58 (10.6%)58 (10.9)0 (0)0.39Shock delivery36 (6.6%)36 (6.7)0 (0)0.62ATP and shock delivery20 (3.6%)20 (3.8)0 (0)1.00VT ablation6 (1.1%)6 (1.1)0 (0)1.00[^2]

Discussion {#sec4}
==========

Our study represents a large data-set evaluating the impact of adding a subcutaneous array in patients with ineffective safety margin testing following ICD-implantation. In particular, the relevant findings of this study are (1) SQ array implantation decreases DFT by mean 10 J to within safety margin for all patients; (2) the incidence of ineffective SMT was negatively affected by younger age and non-ischemic cardiomyopathy; and (3) there were no severe array related adverse events in any of the patients undergoing SQ array placement.

Efficacy of subcutaneous array implantation {#sec4.1}
-------------------------------------------

Unsuccessful intra-operative SMT testing in terms of at least less than 10 J safety margin or necessity for external defibrillation was observed in 2.8% of our patients. This is significantly lower compared to the numbers in older publications [@bib5], [@bib6] reporting consistently proportions of ∼6% of the patients undergoing ICD implantation. Such patients in our study were younger and had underlying non-ischemic cardiomyopathy, although widely accepted "risk factors" predicting a SMT \<10 J are not available. A study of Trusty et al. failed to reveal any correlation of preoperative characteristics with SMT \<10 J [@bib7]. However, several authors reported a wide spectrum of potential risk factors for SMT \<10 J including high body-mass-index, large left ventricular diameter, or amiodarone medication [@bib8], [@bib9]. It is important to remember that several drugs used for general anesthesia during the implantation procedure can increase the minimally effective defibrillation threshold [@bib10]. Off note, habitual cocaine use can cause high defibrillation thresholds [@bib11], but this might not be relevant in daily clinical practice.

Consistent with other studies [@bib2], [@bib3], [@bib6], adding a subcutaneous array in our study increased SMT by a mean of 10 J (from 31 J to 21 J). The higher the number of "fingers" of the subcutaneous array the lower the effects of the SMT was the main conclusion of a randomized study investigating the efficacy of different array types [@bib3]. The subcutaneous array electrode Medtronic 6996SQ used in our series providing a single defibrillation coil might be potentially the most effective tool to solve the problem of high DFT.

To test or not to test {#sec4.2}
----------------------

In 3 decades of clinical use of the implantable cardioverter defibrillator, defibrillation threshold testing has remained an integral part of the initial implantation procedure [@bib12]. The prevailing rationale for the routine evaluation of SMT has been to ensure appropriate sensing of ventricular fibrillation, system integrity, and effective defibrillation [@bib12]. Early in the development of the transvenous ICD, defibrillation threshold testing was performed by connecting the transvenous lead to an external cardioverter defibrillator using high-voltage cables. The device itself was only implanted when external testing was successful [@bib13]. Over time, device-based testing could be performed. Technically, the DFT is a probabilistic phenomenon requiring multiple shocks to determine with precision. Clinically, the SMT is commonly approximated with 1 or more shocks to terminate induced ventricular fibrillation and ensure a safety margin between the DFT and the maximum output of the ICD. Inadequate safety margins of 10 J between the DFT and maximum ICD energy delivery have been associated with worse clinical outcomes [@bib14]. Contemporary ICD systems using active cans, biphasic waveforms, and intravascular high-voltage leads have considerably lowered the incidence of SMT \<10 J [@bib15], [@bib16]. The reliability of current ICD systems has led implanting physicians to abandon the practice of routine testing of defibrillation efficacy before hospital discharge and annually [@bib12], [@bib13]. Based on a growing body of evidence the clinical utility of the determination of defibrillation efficacy during de-novo implants has been questioned in observational studies [@bib15], [@bib17] as well as in randomized trials [@bib18], [@bib19]. Currently, there is a widely accepted consensus that SMT at the time of ICD-implantation, although it seems to be safe, has no impact on post implant outcomes and first shock efficacy. However, this does not apply to patients undergoing implantation of a subcutaneous ICD, to patients with right sided ICD-implantation, and to patients who might have a potential problem with their ICD-system post implant that might warrant safety margin testing [@bib13]. For the latter groups of patients and for patients with ineffective adequate ICD-shock delivery during daily life subcutaneous array implantation represents a very effective but low risk method for DFT lowering.

Limitations {#sec4.3}
-----------

Several limitations of the study merit further discussion. First, this study is subject to limitations inherent in non-randomized retrospective studies. Second, although the number analyzed patients undergoing ICD implantation is high, the total number of patients finally receiving a SQ array was low. Therefore the conclusions of our study are only preliminary.

Conclusions {#sec5}
===========

Our study demonstrates that SQ array implantation in individuals with SMT \<10 J decreases DFT by mean 10 J to within safety margin for all patients, the incidence of SMT \<10 J was affected by younger age and non-ischemic cardiomyopathy, and there were no severe SQ array related adverse events during follow-up in any of the patients. Although routine intra-operative safety margin testing has decreased significantly over the past years (and will continue doing so in the future) SQ array placement is a very effective but low risk method for selected patients for DFT lowering.
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[^1]: BMI: body mass index; CAD: coronary artery disease; CM: cardiomyopathy; DCM: dilated cardiomyopathy; IQR: interquartile range; LVEF: left ventricular ejection fraction; n: number; n.s.: not significant; pp: primary prevention; SMT: safety margin test; SD: standard deviation; sp: secondary prevention; VF: ventricular fibrillation; VT: ventricular tachycardia.

[^2]: FU: follow up; ATP: anti tachycardia pacing. Additional abbreviations in [Table 1](#tbl1){ref-type="table"}.
